Skip to main content

Animations

MJFF Publications

3241 - 3250 of 8825 Results
Title
Year
  • Year
  • 2023
  • 2017
  • 2016
  • 2025
  • 2010
  • 2018
  • 2017
  • 2012
  • 2015
  • 2018
  • Summary Details
    OPEN
    Title: Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity
    Journal Name: iScience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.isci.2023.107525
    Citation Count: 10
  • Summary Details
    RESTRICTED
    Title: Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient
    Journal Name: Clinical Neuropharmacology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/wnf.0000000000000230
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: A suggested minimum standard deep brain stimulation evaluation for essential tremor
    Journal Name: Journal of the Neurological Sciences
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jns.2016.01.041
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Hypoxic conditioning in Parkinson’s disease: randomized controlled multiple N-of-1 trials
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-025-63324-2
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease
    Journal Name: Neurosurgery
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1227/neu.0b013e3181f53a5c
    Citation Count: 70
  • Summary Details
    OPEN
    Title: Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease
    Journal Name: NeuroImage: Clinical
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nicl.2018.05.006
    Citation Count: 55
  • Summary Details
    OPEN
    Title: Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders
    Journal Name: Frontiers in Human Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnhum.2016.00693
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Childhood Stiff-Person Syndrome Improved with Rituximab
    Journal Name: Case Reports in Neurology
    Publisher: S. Karger AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1159/000339446
    Citation Count: 46
  • Summary Details
    OPEN
    Title: Structural Characterization of LRRK2 Inhibitors
    Journal Name: Journal of Medicinal Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/jm5018779
    Citation Count: 38
  • Summary Details
    OPEN
    Title: Generation of RAB39B knockout isogenic human embryonic stem cell lines to model RAB39B-mediated Parkinson's disease
    Journal Name: Stem Cell Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.scr.2018.02.015
    Citation Count: 9
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.